Monoclonal antibody (mAb) product innovation aim of facility expansion in KansasAugust 23, 2024A $130-million investment through 2026 is expected to bolster production and development of monoclonal antibody-based therapy, including a potential product in canine dermatology.
SPONSORED CONTENTFast Itch Relief for Canine PatientsA treatment for allergic and atopic dermatitis, given just once a day. Visibly improves itch fast. + Learn More Now